Hepatitis B - Annual Epidemiological Report for 2017
In 2017, 30 EU/EEA Member States reported 26 907 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases, 26 262, corresponds to a crude rate of 6.7 cases per 100 000 population.
Chronic hepatitis B infections on the rise since 2008
In 2017, the majority (58%) of the almost 27 000 newly reported hepatitis B cases in the European Union and European Economic Area were classified as chronic infections. This follows a consistent upward trend in reported chronic hepatitis B cases since 2008.
It is always time to test: Spring European Testing Week
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.
Hepatitis C - Annual Epidemiological Report for 2017
In 2017, 31 273 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases, 31 178 cases corresponds to a crude rate of 7.3 cases per 100 000 population.
Hepatitis A - Annual Epidemiological Report for 2016
In 2016, 29 EU/EEA countries reported 12 502 cases of hepatitis A, of which 12 429 (99.4%) were confirmed.
Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA
The scope of this project was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings.
Surveillance systems overview for 2017
This spreadsheet contains all surveillance system overview tables from ECDC's annual epidemiological report for 2017.
- Chikungunya virus disease
- Chlamydia infection
- Crimean-Congo haemorrhagic fever
- Ebola haemorrhagic fever
- Hantavirus infection
- Healthcare-associated infections
- Hepatitis A
- Hepatitis B
- Hepatitis C
- HIV infection
- Invasive Haemophilus influenzae disease
- Lassa fever
- Marburg haemorrhagic fever
- Meningococcal disease
- Pneumococcal disease
- Q fever
- Rift Valley fever
- Severe acute respiratory syndrome (SARS)
- Surgical site infections
- Verotoxigenic Escherichia coli infection
- West Nile virus infection
- Yellow fever
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance